In summary, BsAbs targeting multiple receptors, such as c-MET, EGFR and immune cell receptors, offer a promising approach to cancer immunotherapy by leveraging immune cell cytotoxicity and restoring immune response function. The gene discussed is MET; the disease is cancer.